BioSpace News Archive

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present a corporate update during two upcoming investor conferences

Tauriga Sciences, Inc. announced that it is in discussions with multiple international distributors to expand its Tauri-Gum™ brand internationally.

I-Mab Biopharma announced that National Medical Products Administration (NMPA) approved its IND application for TJM2 to conduct clinical trials in patients with rheumatoid arthritis (RA).

Overexposure to cold can be very dangerous, and it is easier to get hypothermia than most people think.

The Starco Group (TSG) of Santa Monica, CA announces the acquisition of Blue Cross Laboratories (BCL) of Santa Clarita, CA

The U.S. Food and Drug Administration granted accelerated approval to Brukinsa capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients due in December 2019

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of Delaware entered an order approving Sienna’s proposed bidding procedures and Chapter 11 sale process timeline.

BrainsWay Ltd., a global leader in the advanced non-invasive treatment of brain disorders, announced that it will report its third quarter 2019 financial results before the opening of the U.S. financial markets on Monday, November 25, 2019.

Eton Pharmaceuticals, Inc reported financial results for the third quarter ended September 30, 2019 and provided an update on business progress.